A long half-life and slow absorption let one weekly injection maintain steady drug levels.
Native incretin hormones are cleared within minutes by the enzyme DPP-4. Tirzepatide is engineered to resist this breakdown and to bind reversibly to albumin, the most abundant blood protein, via an attached fatty-acid chain. Albumin binding keeps the drug in circulation far longer, extending its half-life to about five days.
After a subcutaneous injection, tirzepatide is absorbed slowly, with peak concentrations typically within a day or two. Because each weekly dose is given before the previous one fully clears, levels accumulate until they plateau — steady state — after roughly four weeks at a given dose. This is one reason dose changes are spaced about four weeks apart.
A ~5-day half-life means drug levels stay relatively stable across the week with a single injection, avoiding the peaks and troughs of short-acting drugs and improving adherence. It also means that if a dose is missed, there is a window (per labeling guidance) in which it can be taken before skipping; clinicians advise following the product instructions exactly.
Tirzepatide is metabolized by proteolytic cleavage into smaller peptides and amino acids. Dedicated studies reported no clinically meaningful dose adjustments for renal or hepatic impairment in the approved labeling, though clinicians still individualize care. Pharmacokinetics were broadly consistent across age, sex and body weight in published analyses.
Pharmacokinetic data come from the manufacturer's branded product. Compounded tirzepatide is prepared by pharmacies and is not FDA-approved; its formulation, concentration and excipients can differ, so branded PK data should not be assumed to apply. Always confirm what you are prescribed with your clinician and pharmacy. See compounded vs brand pharmacology.
Because tirzepatide is absorbed slowly from the injection site, small differences in technique, site and individual physiology can produce modest variation in blood levels — generally without changing the once-weekly schedule. This is part of why site rotation and consistent technique are encouraged. It also underlies the guidance to take a missed dose within a defined window and otherwise skip it: the long half-life means one delayed or missed weekly dose usually causes only a small dip in overall exposure rather than a sudden loss of effect. For people switching products or concentrations — especially between branded and compounded preparations — the amount of drug delivered per unit volume can differ, so the same syringe markings do not necessarily mean the same dose. This is a recurring safety theme with compounded products and a key reason to follow the exact instructions for the specific preparation you are given rather than relying on general knowledge about “tirzepatide.”
Citations are provided for educational reference. This article summarizes published research in plain language and is not medical advice. Always consult a licensed clinician.
Its half-life is about 5 days, so it takes roughly 4–5 weeks (about 5 half-lives) to be largely cleared after the last dose.
Its long half-life keeps levels steady across a week, so one weekly injection is sufficient — unlike short-acting drugs that need daily dosing.
About 4 weeks at a given dose, which is why dose increases are typically spaced about a month apart.